Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

@article{Backman2005RifampinMD,
  title={Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites},
  author={Janne T. Backman and Harri Luurila and Mikko Neuvonen and Pertti J. Neuvonen},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2005},
  volume={78}
}
The pharmacokinetic interactions of the widely used statin atorvastatin with fibrates and enzyme inducers are not known. Therefore we studied the effects of rifampin (INN, rifampicin) and gemfibrozil on the pharmacokinetics of atorvastatin. 
Effect of Cytochrome P450 3A5 Genotype on Atorvastatin Pharmacokinetics and Its Interaction with Clarithromycin
TLDR
To assess the effects of the cytochrome P450 (CYP) 3A genotype, CYP3A5, on atorvastatin pharmacokinetics and its interaction with clarithromycin. Expand
Effects of multiple‐dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers
TLDR
Simultaneous administration of single‐ or multiple‐dose rifampicin 600 mg significantly increases the concentrations of fexofenadine enantiomers by inhibiting OATP transporters. Expand
Update on Rifampin and Rifabutin Drug Interactions
TLDR
To avoid a decreased therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Expand
Effects of atorvastatin metabolites on induction of drug‐metabolizing enzymes and membrane transporters through human pregnane X receptor
TLDR
Atorvastatin metabolites are investigated to investigate whether they exert differential effects on the induction of these genes via activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Expand
Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin
TLDR
Gemfibrozil increases systemic exposure to various different statins, whereas similar effects are not observed with fenofibrate, suggesting it may be a more appropriate choice for coadministration with statins. Expand
Drug-drug Interactions between Atorvastatin and Telmisartan
TLDR
Co-administration of atorvastatin and telmisartan may lead to negligible clinical consequences, and each drug at the present dosage seemed to be insufficient to alter the pharmacokinetic parameters of its counterpart drug. Expand
ERSPECTIVES IN CLINICAL HARMACOLOGY rug interactions with lipid-lowering rugs : Mechanisms and clinical relevance
Lipid-lowering drugs, especially 3-hydroxy-3-methylglutaryl–coenzyme A inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic disease. The benefits of statins areExpand
Gemfibrozil in Combination with Statins—Is It Really Contraindicated?
TLDR
Understanding the metabolism of gemfibrozil and the degree of interaction with the various statins will assist health-care providers to optimize safety when this combination is clinically indicated. Expand
Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study.
TLDR
The pharmacokinetics of rosuvastatin were not significantly changed by coadministration of rifampicin in this small group of healthy male volunteers, although there was considerable interindividual variation in the plasma concentration of ro SUVastatin. Expand
Drug–drug interactions that interfere with statin metabolism
TLDR
The pharmacokinetic aspects of the drug–drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, are discussed and the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions is highlighted. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
TLDR
The effects of bezafibrate and gemfibrozil on the pharmacokinetics of lovastatin were studied to study the effects of fibrates with statins and the underlying mechanism of this adverse reaction remains unclear. Expand
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
TLDR
Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4, and its effect on the pharmacokinetics of simvastatin is investigated. Expand
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
TLDR
The aim was to study the effects of gemfibrozil on the pharmacokinetics of pravastatin. Expand
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
TLDR
The aim of this study was to determine whether gemfibrozil affects the pharmacokinetics of simvastatin and whether it affects CYP3A4 activity in vitro. Expand
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
Midazolam is a short‐acting benzodiazepine that is metabolized by CYP3A enzymes. Rifampin is a potent enzyme inducer that may seriously interact with some substrates of CYP3A4.
Gemfibrozil greatly increases plasma concentrations of cerivastatin
TLDR
The effect of gemfibrozil on cerivastatin pharmacokinetics was studied to study the mechanism of this potentially fatal drug interaction. Expand
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
Itraconazole increases the risk of skeletal muscle toxicity of some 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors by increasing their serum concentrations. We studied possibleExpand
Effect of itraconazole on the pharmacokinetics of atorvastatin
TLDR
The aim of this study was to characterize the effect of itraconazole on the pharmacokinetics of atorvastatin, a new HMG‐CoA reductase inhibitor that is metabolized at least in part by CYP3A4. Expand
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
TLDR
Coadministration of statins and gemfibrozil is associated with an increased risk for myopathy, which may be due in part to a pharmacokinetic interaction, which could increase plasma concentrations of rosuvastatin. Expand
Efficacy of statin therapy: possible effect of phenytoin
TLDR
A patient with familial hypercholesterolaemia and epilepsy in whom the introduction and subsequent discontinuation of phenytoin were associated with marked changes in the lipid response to treatment with simvastatin and atorvastasin is reported. Expand
...
1
2
3
4
5
...